Insmed, Inc. (INSM) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1156001,
    "name": "Insmed, Inc.",
    "stock_name": "Insmed, Inc.",
    "full_name": "Insmed, Inc.",
    "name_url": "stocks-analysis/insmed-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "205.04",
    "chg": -1.56,
    "chgp": "-0.76%",
    "dir": -1,
    "prev_price": "206.60",
    "mcapval": "31,004.45",
    "mcap": "Mid Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US4576693075",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "3.72 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/insmed-inc-1156001-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Insmed, Inc. Hits New 52-Week High of $166.44, Up 173.69%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/insmed-inc-hits-new-52-week-high-of-16644-up-17369-3620103",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/InsmedInc_priceRelatedfactors_3620103.png",
        "date": "2025-10-14 18:45:12",
        "description": "Insmed, Inc. has achieved a new 52-week high, reflecting a significant increase in its stock performance over the past year. Despite operating at a loss, the company maintains a substantial market capitalization and exhibits a high price-to-book ratio, indicating a premium valuation in the pharmaceuticals and biotechnology sector."
      },
      {
        "title": "Insmed, Inc. Hits New 52-Week High of $163.22, Up 170% Yearly",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/insmed-inc-hits-new-52-week-high-of-16322-up-170-yearly-3607997",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/InsmedInc_priceRelatedfactors_3607997.png",
        "date": "2025-10-09 20:06:16",
        "description": "Insmed, Inc. has achieved a new 52-week high of USD 163.22, reflecting a significant increase in its stock price over the past year. With a market capitalization of approximately USD 31 billion, the company shows strong market momentum despite ongoing financial challenges, including a low return on equity."
      },
      {
        "title": "Insmed, Inc. Hits New 52-Week High of $162.44, Up 171% Year-Over-Year",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/insmed-inc-hits-new-52-week-high-of-16244-up-171-year-over-year-3604300",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/InsmedInc_priceRelatedfactors_3604300.png",
        "date": "2025-10-08 16:42:04",
        "description": "Insmed, Inc. has achieved a new 52-week high, reflecting a significant increase in its stock performance over the past year. With a market capitalization of approximately USD 31 billion, the company maintains a high price-to-book ratio and a negative debt-to-equity ratio, indicating a focus on growth despite current losses."
      },
      {
        "title": "Insmed, Inc. Hits New 52-Week High of $160.62, Up 164% Yearly",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/insmed-inc-hits-new-52-week-high-of-16062-up-164-yearly-3601595",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/InsmedInc_priceRelatedfactors_3601595.png",
        "date": "2025-10-07 21:45:27",
        "description": "Insmed, Inc. has achieved a new 52-week high of USD 160.62, reflecting a significant performance increase of 164.24% over the past year. With a market capitalization of USD 31 billion, the company maintains a high price-to-book ratio and a unique financial structure, despite ongoing losses."
      },
      {
        "title": "Insmed, Inc. Hits New 52-Week High of $158.19, Up 162%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/insmed-inc-hits-new-52-week-high-of-15819-up-162-3595602",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/InsmedInc_priceRelatedfactors_3595602.png",
        "date": "2025-10-06 17:29:36",
        "description": "Insmed, Inc. has achieved a new 52-week high of USD 158.19, reflecting a significant increase in its stock price over the past year. With a market capitalization of approximately USD 31 billion, the company has garnered attention despite being loss-making and not offering dividends. Its financial structure includes a notable price-to-book ratio and a negative debt-to-equity ratio."
      },
      {
        "title": "Insmed, Inc. Hits Day High with Strong 5.09% Intraday Surge",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/insmed-inc-hits-day-high-with-strong-509-intraday-surge-3585856",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/InsmedInc_priceRelatedfactors_3585856.png",
        "date": "2025-10-01 16:10:14",
        "description": "Insmed, Inc. has seen a significant rise in its stock performance, reaching an intraday high and outperforming the S&P 500 over the past month and year. However, the company faces financial challenges, including negative operating cash flow and a high price-to-book ratio, indicating potential underlying pressures."
      },
      {
        "title": "Is Insmed, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-insmed-inc-technically-bullish-or-bearish-3545723",
        "imagepath": "",
        "date": "2025-09-20 19:17:03",
        "description": "As of 21 July 2025, the technical trend for Insmed, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators from the MACD, which is bullish on both weekly and monthly time frames, and the daily moving averages also indicating bullish momentum. However, the RSI shows bearish signals on both weekly and monthly time frames, suggesting some weakness. The Bollinger Bands are mildly bullish weekly and bullish monthly, while the KST is bullish weekly but mildly bearish monthly. The Dow Theory indicates a mildly bullish stance on both time frames, and the OBV is bullish for both weekly and monthly periods.\n\nIn terms of performance, Insmed has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 111.27% compared to the S&P 500's 12.22%, and a 1-year return of 100.16% versus 17.14%. Overall, while there are some mixed signals, the ..."
      },
      {
        "title": "Is Insmed, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-insmed-inc-overvalued-or-undervalued-3542406",
        "imagepath": "",
        "date": "2025-09-20 17:52:04",
        "description": "As of 22 February 2019, the valuation grade for Insmed, Inc. has moved from does not qualify to risky, indicating a significant change in its perceived risk profile. The company appears to be overvalued, with a Price to Book Value of 135.23 and negative EV to EBIT and EV to EBITDA ratios of -15.70 and -15.91, respectively. Additionally, the latest ROCE and ROE figures are alarming at -483.80% and -896.32%, respectively, suggesting severe inefficiencies in capital utilization and shareholder returns.\n\nIn comparison to its peers, Insmed, Inc. has a P/E ratio of -32.49, which is less favorable than Intra-Cellular Therapies, Inc. at -187.76 and Karuna Therapeutics, Inc. at -29.01. This places Insmed in a precarious position within the pharmaceuticals and biotechnology sector. Notably, Insmed has outperformed the S&P 500 over multiple periods, with a year-to-date return of 111.27% compared to the S&P 500's 12.22..."
      }
    ],
    "total": 13,
    "sid": "1156001",
    "stock_news_url": "https://www.marketsmojo.com/news/insmed-inc-1156001"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Insmed, Inc. Hits New 52-Week High of $166.44, Up 173.69%

2025-10-14 18:45:12

Insmed, Inc. has achieved a new 52-week high, reflecting a significant increase in its stock performance over the past year. Despite operating at a loss, the company maintains a substantial market capitalization and exhibits a high price-to-book ratio, indicating a premium valuation in the pharmaceuticals and biotechnology sector.

Insmed, Inc. Hits New 52-Week High of $163.22, Up 170% Yearly

2025-10-09 20:06:16

Insmed, Inc. has achieved a new 52-week high of USD 163.22, reflecting a significant increase in its stock price over the past year. With a market capitalization of approximately USD 31 billion, the company shows strong market momentum despite ongoing financial challenges, including a low return on equity.

Insmed, Inc. Hits New 52-Week High of $162.44, Up 171% Year-Over-Year

2025-10-08 16:42:04

Insmed, Inc. has achieved a new 52-week high, reflecting a significant increase in its stock performance over the past year. With a market capitalization of approximately USD 31 billion, the company maintains a high price-to-book ratio and a negative debt-to-equity ratio, indicating a focus on growth despite current losses.

Insmed, Inc. Hits New 52-Week High of $160.62, Up 164% Yearly

2025-10-07 21:45:27

Insmed, Inc. has achieved a new 52-week high of USD 160.62, reflecting a significant performance increase of 164.24% over the past year. With a market capitalization of USD 31 billion, the company maintains a high price-to-book ratio and a unique financial structure, despite ongoing losses.

Insmed, Inc. Hits New 52-Week High of $158.19, Up 162%

2025-10-06 17:29:36

Insmed, Inc. has achieved a new 52-week high of USD 158.19, reflecting a significant increase in its stock price over the past year. With a market capitalization of approximately USD 31 billion, the company has garnered attention despite being loss-making and not offering dividends. Its financial structure includes a notable price-to-book ratio and a negative debt-to-equity ratio.

Insmed, Inc. Hits Day High with Strong 5.09% Intraday Surge

2025-10-01 16:10:14

Insmed, Inc. has seen a significant rise in its stock performance, reaching an intraday high and outperforming the S&P 500 over the past month and year. However, the company faces financial challenges, including negative operating cash flow and a high price-to-book ratio, indicating potential underlying pressures.

Is Insmed, Inc. technically bullish or bearish?

2025-09-20 19:17:03

As of 21 July 2025, the technical trend for Insmed, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators from the MACD, which is bullish on both weekly and monthly time frames, and the daily moving averages also indicating bullish momentum. However, the RSI shows bearish signals on both weekly and monthly time frames, suggesting some weakness. The Bollinger Bands are mildly bullish weekly and bullish monthly, while the KST is bullish weekly but mildly bearish monthly. The Dow Theory indicates a mildly bullish stance on both time frames, and the OBV is bullish for both weekly and monthly periods. In terms of performance, Insmed has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 111.27% compared to the S&P 500's 12.22%, and a 1-year return of 100.16% versus 17.14%. Overall, while there are some mixed signals, the ...

Is Insmed, Inc. overvalued or undervalued?

2025-09-20 17:52:04

As of 22 February 2019, the valuation grade for Insmed, Inc. has moved from does not qualify to risky, indicating a significant change in its perceived risk profile. The company appears to be overvalued, with a Price to Book Value of 135.23 and negative EV to EBIT and EV to EBITDA ratios of -15.70 and -15.91, respectively. Additionally, the latest ROCE and ROE figures are alarming at -483.80% and -896.32%, respectively, suggesting severe inefficiencies in capital utilization and shareholder returns. In comparison to its peers, Insmed, Inc. has a P/E ratio of -32.49, which is less favorable than Intra-Cellular Therapies, Inc. at -187.76 and Karuna Therapeutics, Inc. at -29.01. This places Insmed in a precarious position within the pharmaceuticals and biotechnology sector. Notably, Insmed has outperformed the S&P 500 over multiple periods, with a year-to-date return of 111.27% compared to the S&P 500's 12.22...

View All News